Who Paid My Doc
Charles Mouch
Interventional Pain Medicine San Marcos, TX Medical Doctor
NPI 1851740583 CMS profile 8801920
1304 Wonder World Dr, San Marcos, TX 78666
General payments
$56,982
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Charles Mouch of San Marcos, TX is reported in the CMS Open Payments database as having received $56,982 across 557 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,494 | 80 | |
| 2024 | General | $26,321 | 151 | |
| 2023 | General | $5,958 | 120 | |
| 2022 | General | $9,903 | 162 | |
| 2021 | General | $8,342 | 42 | |
| 2020 | General | $1,965 | 2 |
Beside peers
- Charles Mouch
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Charles Mouch were reported at $4,494. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Charles Mouch | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $684 | $216–$2,079 | $163 |
| 2020 | $1,965 | $382 | $122–$1,109 | $114 |
| 2021 | $8,342 | $552 | $167–$1,554 | $132 |
| 2022 | $9,903 | $605 | $187–$1,924 | $149 |
| 2023 | $5,958 | $671 | $195–$1,915 | $160 |
| 2024 | $26,321 | $684 | $206–$1,837 | $164 |
| 2025 | $4,494 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 27 drugsPart D claims
3,196
Drug cost
$133,313
Branded share of claims
66.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 1,596 | $41,428 | |
| Belbuca Buprenorphine Hcl | Brand | 33 | $26,587 | |
| Xtampza Er Oxycodone Myristate | Brand | 31 | $15,225 | |
| Buprenorphine | Generic | 36 | $12,744 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 296 | $6,695 | |
| Nucynta Tapentadol Hcl | Brand | 12 | $6,618 | |
| Fentanyl | Generic | 40 | $4,356 | |
| Pregabalin | Generic | 110 | $3,007 | |
| Lidocaine | Generic | 22 | $2,557 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 79 | $1,880 |
The 10 drugs with the highest cost, of 27 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 78 billing codesPaid by Medicare
$321,809
Medicare patients
506
Services billed
30,495
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 35% | |
| Depression | 33% | |
| Diabetes | 32% | |
| Chronic kidney disease | 29% | |
| Heart failure | 19% | |
| Osteoporosis | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 279 | 28,301 | $2,884 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 74 | 85 | $645 |
| Injection, methylprednisolone acetate, 20 mg J1020 | Office | 33 | 37 | $193 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 32 | 39 | $166 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
557 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Texas
Gabor Racz
Interventional Pain Medicine · Lubbock, TX
Pankaj Mehta
Interventional Pain Medicine · Killeen, TX
Chad Stephens
Interventional Pain Medicine · Southlake, TX
Ankur Khosla
Interventional Pain Medicine · Shenandoah, TX
Brian Rich
Interventional Pain Medicine · Decatur, TX
Brian Bruel
Interventional Pain Medicine · Houston, TX
Related records
Interventional Pain Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.